Perceptive Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Perceptive Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-55,175	Closed	-$26.7M	–	157
2020 Q4	$26.7M	Buy	55,175 +50,175	+1,004%	+$27.1M	0.29%	72
2020 Q3	$2.8M	Sell	5,000 -10,000	-67%	-$6.06M	0.04%	112
2020 Q2	$9.35M	Sell	15,000 -65,000	-81%	-$36.9M	0.15%	83
2020 Q1	$39.1M	Buy	+80,000	New	+$33M	1.02%	22
2018 Q1	–	Sell	-20,000	Closed	-$6.96M	–	151
2017 Q4	$7.52M	Buy	+20,000	New	+$8.1M	0.25%	61
2013 Q3	–	Sell	-139,310	Closed	-$31.3M	–	116
2013 Q2	$31.3M	Buy	+139,310	New	+$32.4M	3.16%	8

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perceptive Advisors's REGN Position: Q1 2021 in Review

Perceptive Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2021, closing a stake of 55,175 shares — an estimated $26.7M sold.

Perceptive Advisors first reported a position in REGN in Q2 2013 and held it in 6 quarters. The position peaked at $39.1M in Q1 2020. 924 funds tracked by Wall St. Rank hold REGN as of Q1 2021.

Perceptive Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Perceptive Advisors sold 55,175 Regeneron Pharmaceuticals shares in Q1 2021, an estimated $26.7M.
Perceptive Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Perceptive Advisors's Regeneron Pharmaceuticals position peaked at $39.1M in Q1 2020.
924 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2021.

Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.